A US drug company has agreed to pay out $1.6bn (£1bn) after improperly marketing a mood-stabilising drug in a settlement thought to be the largest of its kind involving a single drug. Abbott Laboratories encouraged its sales teams to market Depakote for uses that were not approved by regulators, the US justice department said.